Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): A case report
Neurotrophic keratopathy is a potential consequence of herpes simplex virus (HSV) or varicella zoster virus (VZV) infection. The treatment is based on artificial tears and the withdrawal of preserved eye drops or other types of epitheliotoxic topical medicines. Autologous serum or amniotic membrane...
Saved in:
Published in | Journal francais d'ophtalmologie Vol. 35; no. 3; p. 187.e1 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | French |
Published |
France
01.03.2012
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Neurotrophic keratopathy is a potential consequence of herpes simplex virus (HSV) or varicella zoster virus (VZV) infection. The treatment is based on artificial tears and the withdrawal of preserved eye drops or other types of epitheliotoxic topical medicines. Autologous serum or amniotic membrane transplantation may also be used in severe cases, but their cost and safety are still under debate. We report a case of a patient with a history of herpes zoster ophthalmicus, who developed a persistent epithelial ulcer after cataract surgery, with no improvement despite 3 weeks of artificial tears (eight drops per day). A new ophthalmologic solution based on a regenerating agent (RGTA, Cacicol20(®)) was then used, with a dosage of two eye drops per week for 6 weeks. Improvement was observed 1 week later, and complete healing was obtained in less than 3 weeks, with no side effects. This heparin mimetic, which may stimulate extracellular matrix healing, may be a possible alternative therapy to autologous serum or amniotic membrane transplantation in severe neurotrophic ulcer. However, randomized studies are necessary to validate this observation. |
---|---|
AbstractList | Neurotrophic keratopathy is a potential consequence of herpes simplex virus (HSV) or varicella zoster virus (VZV) infection. The treatment is based on artificial tears and the withdrawal of preserved eye drops or other types of epitheliotoxic topical medicines. Autologous serum or amniotic membrane transplantation may also be used in severe cases, but their cost and safety are still under debate. We report a case of a patient with a history of herpes zoster ophthalmicus, who developed a persistent epithelial ulcer after cataract surgery, with no improvement despite 3 weeks of artificial tears (eight drops per day). A new ophthalmologic solution based on a regenerating agent (RGTA, Cacicol20(®)) was then used, with a dosage of two eye drops per week for 6 weeks. Improvement was observed 1 week later, and complete healing was obtained in less than 3 weeks, with no side effects. This heparin mimetic, which may stimulate extracellular matrix healing, may be a possible alternative therapy to autologous serum or amniotic membrane transplantation in severe neurotrophic ulcer. However, randomized studies are necessary to validate this observation. |
Author | De Monchy, I Kaswin, G Gendron, G Labetoulle, M M'Garrech, M Labbé, A Pogorzalek, N |
Author_xml | – sequence: 1 givenname: I surname: De Monchy fullname: De Monchy, I organization: Service d'ophtalmologie, CHU Bicêtre, Assistance publique-Hôpitaux de Paris, 78, avenue du Général-Leclerc, 94270 Le Kremlin-Bicêtre, France – sequence: 2 givenname: A surname: Labbé fullname: Labbé, A – sequence: 3 givenname: N surname: Pogorzalek fullname: Pogorzalek, N – sequence: 4 givenname: G surname: Gendron fullname: Gendron, G – sequence: 5 givenname: M surname: M'Garrech fullname: M'Garrech, M – sequence: 6 givenname: G surname: Kaswin fullname: Kaswin, G – sequence: 7 givenname: M surname: Labetoulle fullname: Labetoulle, M |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22015067$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j9FKwzAUhoMobs49gDeSS71oPUmbpfVuDJ3CRJB5PdL2ZOtYm5Ck6Hx6I-rVB-f8_8c5F-S0Nz0ScsUgZcBmd_t0r03KgbEUyhSAn5AxkzJLQJRyRKbetxWwcsalEOycjHiMCpjJMcEX1astdtgHajTdobPo6ZfxAR3tcXAmOGN3bU2HQx1Hg2_7LVVx9UE7FVz7SUMsKXukURMlN2_L9fz2ns5prTxSh9a4cEnOtDp4nP5xQt4fH9aLp2T1unxezFeJZTmEpBQ8YwiiyDNZ1LwSUiqQhf45VZZZLoSukTdNBECGCptCIeRC50WVVxr4hFz_eu1QddhsrGs75Y6b_3_5NyajWPI |
ContentType | Journal Article |
Copyright | Copyright © 2011 Elsevier Masson SAS. All rights reserved. |
Copyright_xml | – notice: Copyright © 2011 Elsevier Masson SAS. All rights reserved. |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1016/j.jfo.2011.09.002 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
DocumentTitleAlternate | Utilisation d'un agent biodégradable de la régénération tissulaire (RGTA) dans le traitement d'un ulcère trophique résistant d'origine zostérienne : à propos d'un cas |
EISSN | 1773-0597 |
ExternalDocumentID | 22015067 |
Genre | English Abstract Journal Article Case Reports |
GroupedDBID | ABJNI ALMA_UNASSIGNED_HOLDINGS CGR CUY CVF ECM EIF NPM |
ID | FETCH-LOGICAL-p140t-95231e0584378c2b577a078f5067793455fce2dd5fc003eaed8ae045f48b4bf02 |
IngestDate | Fri Feb 23 03:05:33 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | French |
License | Copyright © 2011 Elsevier Masson SAS. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p140t-95231e0584378c2b577a078f5067793455fce2dd5fc003eaed8ae045f48b4bf02 |
PMID | 22015067 |
ParticipantIDs | pubmed_primary_22015067 |
PublicationCentury | 2000 |
PublicationDate | 2012-Mar |
PublicationDateYYYYMMDD | 2012-03-01 |
PublicationDate_xml | – month: 03 year: 2012 text: 2012-Mar |
PublicationDecade | 2010 |
PublicationPlace | France |
PublicationPlace_xml | – name: France |
PublicationTitle | Journal francais d'ophtalmologie |
PublicationTitleAlternate | J Fr Ophtalmol |
PublicationYear | 2012 |
SSID | ssib019627551 ssib053390985 |
Score | 2.0410087 |
Snippet | Neurotrophic keratopathy is a potential consequence of herpes simplex virus (HSV) or varicella zoster virus (VZV) infection. The treatment is based on... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 187.e1 |
SubjectTerms | Administration, Ophthalmic Aged, 80 and over Anti-Ulcer Agents - administration & dosage Anti-Ulcer Agents - therapeutic use Corneal Ulcer - drug therapy Corneal Ulcer - etiology Glycosaminoglycans - administration & dosage Herpes Zoster - complications Herpes Zoster - drug therapy Herpes Zoster Ophthalmicus - complications Herpes Zoster Ophthalmicus - drug therapy Humans Male Ophthalmic Solutions - administration & dosage Optic Nerve Diseases - drug therapy Optic Nerve Diseases - etiology Regeneration - drug effects Regeneration - physiology |
Title | Management of herpes zoster neurotrophic ulcer using a new matrix therapy agent (RGTA): A case report |
URI | https://www.ncbi.nlm.nih.gov/pubmed/22015067 |
Volume | 35 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swGBVp97KX0tJdeht66KDDOCSOHdl7C10vjFFKSaFvRZKlXlMbN2Fbfkh_b48ku3ZCxra-OEYydqzv-NPRdxMhuwwcgadR7EdaSj_kUvixTrifBB2h0pD1uLIBsif94_Pw-0V00Wo9NaKWJmPRltOFeSWvkSraIFeTJfsfkn25KRpwDvniCAnj-E8yrmNXHOcrcvXoTU3aRuHZQpXjIsuvb6Q3uZdomli7ADe7iHsjU5r_l-fSr357_KosPXp2NBx8DhKXsC4xxZVehUUkVptNOfjNo4f3ZngQePzI6tIXsHyzSkNez9pnf3AhnIN-xph6ml1lxRQT1t2Mi8hsdle42ICjpo3CBHtUQVpt5fQqYyZM0IXiVorX1SkpAdZraNFuzNqqu1DBO1vDbftWZ2X9VVNvNGheixHKR1biQWALKLK_987V3K66lsgSi432PKltQF2zXVFU-1LBl5NOEkeVy9wGD879PVNyurzl3PLF0pjhKlkpRUcHDkxrpKWLdaJqINFMUwck6oBEm0CiFkjUAolydP2kDki0BBK1QKJ7BkZfvtIBNRCiDkLvyPnhwXD_2C_33_BzLLvHfhKB_KsOKGqPxTIQEWMcjFKb14BaDyN83ypIU_xgblBcpTFXWCLoMBah0J3gPVl-yB7UR0KVSRbqgy9qJcJQ97lIwVsluLfA-oP3NsgHNyqXuSuyclmN1-Yfe7bI2xpr2-SNxletdkARx-KTldgzDiBiag |
link.rule.ids | 783 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Management+of+herpes+zoster+neurotrophic+ulcer+using+a+new+matrix+therapy+agent+%28RGTA%29%3A+A+case+report&rft.jtitle=Journal+francais+d%27ophtalmologie&rft.au=De+Monchy%2C+I&rft.au=Labb%C3%A9%2C+A&rft.au=Pogorzalek%2C+N&rft.au=Gendron%2C+G&rft.date=2012-03-01&rft.eissn=1773-0597&rft.volume=35&rft.issue=3&rft.spage=187.e1&rft_id=info:doi/10.1016%2Fj.jfo.2011.09.002&rft_id=info%3Apmid%2F22015067&rft_id=info%3Apmid%2F22015067&rft.externalDocID=22015067 |